Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial - Concepedia

Concepedia

Publication | Closed Access

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

2.2K

Citations

21

References

2018

Year

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman,

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaAxicabtagene CiloleucelMedicineImmunologyPharmacotherapyLong-term SafetyImmunotherapyOncologyRadiation OncologyCancer ResearchPhase 1–2

References

	Year	Citations

Page 1

Page 1